|
In a major policy shift that promises to significantly ease capital flow for pharmaceutical manufacturers, the Government of Gujarat has formally unlinked capital subsidies from bank loans under its newly notified industrial framework.
Issued via a Government Resolution on September 25, 2026, the Scheme for Assistance to Micro, Small, and Medium Enterprises under the Viksit Gujarat Industrial Policy 2026 will now base financial incentives on actual investment rather than debt.
Under the earlier industrial framework, capital subsidies were strictly calculated against bank term loans, effectively denying benefits to self-funded projects and reducing support for low-geared units. The revised scheme removes this constraint by calculating a 25 per cent to 35 per cent capital subsidy directly on the Eligible Fixed Capital Investment, covering tangible outlays in land, buildings, plant, and machinery.
According to pharma industry experts from Gujarat, this reform directly benefits active pharmaceutical ingredient, bulk drug, and formulation manufacturers who rely heavily on internal accruals, promoter funding, or equity to finance state-of-the-art facilities. By disconnecting the subsidy from borrowing, units upgrading to advanced automation or expanding capacity can secure full government assistance without taking on unnecessary interest burdens or complex loan approvals.
The baseline impact is substantial across Gujarat’s manufacturing hubs. For instance, a Rs. 10 crore pharma unit set up in a Category A taluka under a Rs. 6 crore term loan previously received 35 per cent on the borrowed Rs. 6 crore (Rs. 2.10 crore); under the new Eligible Fixed Capital Investment structure, the same unit receives 35 per cent on the full Rs. 10 crore project cost, yielding Rs. 3.50 crore regardless of how much debt was raised.
Beyond direct capital support, the 2026 scheme introduces a flexible incentive stack capped at an overall cumulative ceiling of up to 45 per cent of Eligible Fixed Capital Investment in Category A talukas and 35 per cent in Category B talukas. Units opting for debt can access a 7 per cent annual interest subsidy for five years, alongside power tariff assistance of Rs. 1 to Rs. 2 per unit, creating an adaptable safety net across operating models.
The policy also recalibrates classification thresholds to accommodate rising capital intensity, expanding the small enterprise definition up to Rs. 25 crore in plant and machinery and medium enterprises up to Rs. 125 crore. All eligible investments made on or after January 1, 2026, qualify under the new policy scope, bringing modern, high-value pharma manufacturing units squarely under the incentive fold.
Projects already being set up as of June 1, 2026, have a six-month deadline from September 25 to decide whether to stay with the old subsidy scheme or switch to the new 2026 policy. Once this choice is made, it cannot be changed. With the choice being standard and irreversible once selected, pharmaceutical entrepreneurs across the state are now re-evaluating their funding models to maximize financial returns under Gujarat’s updated industrial roadmap.
Gujarat's pharmaceutical manufacturing ecosystem forms a critical pillar of India's healthcare supply chain. Across the state, there are over 3,500 licensed pharmaceutical manufacturing units, including major national and global players such as Zydus Lifesciences, Torrent Pharmaceuticals, Sun Pharma, Alembic, and Intas Pharmaceuticals. MSMEs form the backbone of this industrial base, accounting for more than 42 lakh registered MSME units statewide across diverse manufacturing sectors, with over 3,000 small and micro pharmaceutical enterprises operating as vital suppliers of bulk drugs, intermediates, formulations, and packaging solutions. Identified as one of the 21 High-Growth Thrust Sectors under the Viksit Gujarat Industrial Policy 2026, the pharma sector is positioned to leverage green production technologies, Zero Liquid Discharge support, advanced R&D incentives, and enhanced market development assistance to drive global export competitiveness.
|